Psychiatric Medication Report

What This Report Does

The Psychiatric Medication Report analyzes your CYP2D6 results and CYP2C19 genotypes and maps them against CPIC clinical guidelines for psychiatric medications. These two genes metabolize the majority of commonly prescribed antidepressants, ADHD medications, and antipsychotics.

Your report identifies your metabolizer phenotype for each gene and flags specific medications where your genetics may affect drug metabolism, exposure, or side-effect risk. Results are organized by condition (depression & anxiety, ADHD) and include a clinician pocket summary you can share with your prescriber.

Medications Covered

The report covers psychiatric medications with CPIC-level evidence for CYP2D6 or CYP2C19 drug-gene interactions, including:

• SSRIs: escitalopram (Lexapro), sertraline (Zoloft), citalopram (Celexa), paroxetine (Paxil), fluoxetine (Prozac), fluvoxamine (Luvox)
• SNRIs: venlafaxine (Effexor)
• Tricyclic antidepressants: amitriptyline, nortriptyline, clomipramine, imipramine, desipramine
• ADHD medications: atomoxetine (Strattera)
• Antipsychotics: clozapine (Clozaril), flupentixol (Fluanxol)

This list represents medications with current CPIC or DPWG guideline evidence. Coverage may expand as new guidelines are published. For a broader view of CYP2D6-metabolized antidepressants, see our CYP2D6 and antidepressants guide.

How It Works

1. Upload your DNA data from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA.
2. Your raw data is analyzed to extract CYP2D6 and CYP2C19 variants and assign star alleles, diplotypes, and metabolizer phenotypes.
3. Results are mapped to CPIC guidelines for each psychiatric medication, identifying interactions where your genotype may affect drug metabolism.
4. Your report is generated with a priority dashboard, condition-based groupings, decision table, and clinician pocket summary.

For details on the analysis pipeline, see our methodology page or read about how pharmacogenomic testing works.

Who This Report Is For

• People currently taking or considering antidepressants, ADHD medications, or antipsychotics who want to understand how their genetics may affect drug metabolism.
• People who have experienced side effects or lack of response with psychiatric medications and want to explore whether pharmacogenomics could provide useful context for their prescriber.
• Anyone with 23andMe, AncestryDNA, or other consumer DNA data who wants to extract pharmacogenomic insights from raw data they already have.

The Genes Behind the Report

The report focuses on two pharmacogenes with the strongest clinical evidence for psychiatric medication metabolism:

• The CYP2D6 gene — Metabolizes approximately 25% of all prescribed medications, including many antidepressants (fluoxetine, paroxetine, venlafaxine, nortriptyline), antipsychotics (clozapine, flupentixol), and atomoxetine for ADHD.
• The CYP2C19 gene — The primary metabolic pathway for escitalopram, sertraline, citalopram, and several tricyclic antidepressants including amitriptyline and clomipramine.

Your metabolizer status for each gene determines whether CPIC guidelines flag any psychiatric medications for potential dose adjustments or alternative therapy considerations.

What the Report Includes

• Risk snapshot: Summary of significant and moderate findings across your psychiatric medication profile.
• Condition-based groupings: Medications organized by depression & anxiety, ADHD, and other psychiatric indications.
• Decision table: Each flagged medication with gene, guideline action, and CPIC evidence level.
• Detailed gene findings: Your CYP2D6 and CYP2C19 diplotypes, activity scores, and phenotype classifications.
• Clinician pocket summary: A one-page overview formatted for your healthcare provider.

Limitations

• This report analyzes CYP2D6 and CYP2C19 only. Other genes and non-genetic factors also influence psychiatric medication response.
• Consumer genotyping arrays cannot detect gene deletions or duplications, which affect some CYP2D6 phenotype classifications.
• Pharmacogenomic results do not predict whether a medication will reduce your symptoms. They indicate how your genetics may affect drug metabolism.
• This is not medical advice. All medication decisions should be made with your healthcare provider. See our full limitations page.

Learn More

• Pharmacogenomic Testing for Depression — What your DNA can and cannot tell you about antidepressant response.
• CYP2D6 and Antidepressants — Which antidepressants are metabolized by CYP2D6 and what that means.
• CYP2C19 and SSRI Metabolism — Why CYP2C19 matters for escitalopram, sertraline, and other SSRIs.
• Pharmacogenomics for ADHD — What genetic testing can and cannot tell you about ADHD medications.
• Pharmacogenomics for Anxiety — What genetic testing reveals about anxiety medication metabolism.
• What Is Pharmacogenomics? — An introduction to the science behind this report.
• What To Do With Your 23andMe Raw Data — How to extract pharmacogenomic insights from DNA data you already have.
• Nutrition & Methylation Report — How your DNA affects folate, B12, vitamin D, and other nutrient metabolism.

Frequently Asked Questions